周京颖教授 – 生物醫學學院

周京颖教授

Assistant Professor

39431350

zhoujy@cuhk.edu.hk

Room 509A, 3/F, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

Publons

ORCID

个人简介

Prof. ZHOU Jingying (周京颖) obtained her Ph.D. degree in Microbiology from the AIDS Institute, Department of Microbiology, The University of Hong Kong (HKU) in 2013 and received the Awards for Outstanding Research Postgraduate Student (HKU). She continued her research as a postdoctoral fellow in Prof. Alfred Cheng’s lab, School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK) and became a Research Assistant Professor in 2018. Prof. Zhou has published in international journals including Gut, Journal of Clinical Investigation, Cancer Research, Nature Communications, Nature Microbiology and served as co-inventor of two U.S. patents on DNA vaccines. She has received academic awards including recognitions from the American Association of Immunologists (AAI), United European Gastroenterology (UEG) and AstraZeneca. Prof. Zhou’s current research interests are innate and adaptive immune regulation in cancer, with particular focus on the mechanisms of tumor microenvironment in hepatocellular carcinoma (HCC) and aiming at the enhancement of cancer immunotherapy.

Research Interests

Lipid metabolic regulations in liver immunity.
Neuroimmunomodulations in liver microenvironment.
Liver microenvironment in cancer metastasis and immunotherapy resistance.

Selected Publications

Zeng, X., Zhou, J.^#, Xiong, Z., Sun, H., Yang, W., Mok, M., Wang, J., Li, J., Liu, M., Tang, W., Feng, Y., Wang, H.K.S., Tsang, S.W., Chow, K.L., Yeung, C., Wong, J., Lai, P.B.S., Chan, A.W.H., To, K.F., Chan, S.L., Xia, Q., Xue, J., Chen, X., Yu, J., Peng, S., Sung, J.J.Y., Kuang, M., Cheng, A.S.#. (2021). Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cell Mol Immunol. 2021 Apr;18(4):1005-1015. [2/28] [IF: 11.53]. Immunology & Microbiology, 58/556.
Yang, W.^#, Feng, Y.^#, Zhou, J.^#, Cheung, O.K., Cao, J.Q., Wang, J., Tang, W.S., Tu, Y.L., Xu, L.L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P.B., Chan, S.L., Chan, A.W., Tan, P., Chen, Z., Sung, J.J., Yip, K.Y.L., To, K.F., Cheng, A.S. (2021). Enhancer reprogramming by selective HDAC8 inhibition potentiates T cell infiltration and durable antitumor efficacy of PD-L1 blockade. Sci Transl Med. 2021 Apr 7;13(588). [IF: 17.956] Medicine, (miscellaneous) 23/2447.
Kwong, T.T., Wong, C.H., Zhou, J. , Cheng, A.S., Sung, J.J., Chan, A.W., Chan, S.L. (2021). Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Rep., 2021 Apr 1; 3 (2),100224. [3/7] .
Liu, M.^#, Zhou, J.^#, Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O.K.W., Sun, H., Zeng, X., Tang, W., Mok, M., Wong, J., Yeung, P.C., Lai, P.B.S., Jin, H., Chen, J., Chan, S.L., Chan, A.W.H., To, K.F., Chen, Z., Sung, J.J., Chen, M., Cheng, A.S. (2020). Targeting Monocyte-intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma. Gut. 2020 Feb; 69(2):365-379. [2/23] [IF: 23.059] Gastroenterology, 2/144] .
Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M.T.S., Tang, W., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Cheung, Y.S., Lai, P.B.S., Wang, H.K.S., Tsang, S.W., Chow, K.L., Hu, M., Liu, R., Huang, L., Yang, B., Yang, P., To, K.F., Sung, J.J.Y., Wong, G.L.H., Wong, V.W.S., & Cheng, A.S. (2018). An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat Commun. 2018 Dec; 6;9(1):5214. [5/26] [IF: 12.121] Biochemistry, Genetics and Molecular Biology, (miscellaneous) 11/254.
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Wong, J., Chong, C.C.N., Lai, P.B.S., Wang, H.K., Tsang, S.W., Goodwin, T., Liu, R., Huang, L., Chen, Z., Sung, J.J., Chow, K.L., To, K.F., & Cheng, A.S. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018 May; 67:931-944. [1/20] [IF: 23.059]. Gastroenterology 2/144,.
Cheung, K.L., Kwok, H.Y., Huang, Y.R., Chen, M., Mo, Y.F.,Wu, X.L., Lam, K.S., Kong, H.K., Lau, C.K., Zhou, J., Li, J.J., Cheng, L., Lee, B.K., Peng, Q.L., Lu, X.F., An, M.H., Wang, H., Shang, S., Zhou, B.P., Wu, H., Xu, A.M., Yuen, K.Y., & Chen Z. (2017). Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during Aacute HIV type 1 infection. Nat Microbiol. 2017 Oct; 2(10):1389-1402. [10/23] [IF: 15.540] Immunology & Microbiology,, 14/556.
Tan, Z.^#, Zhou, J.^#, Cheung, K.L., Yu, Z., Cheung, K.W., Liang, J., Wang, H., Lee, B., Man, K., Liu, L., Yuen, K., & Chen, Z. (2014). Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Res. 2014 Nov; 74; 6010. [2/12] [IF: 12.701] Oncology, 20/354.
Zhou J.^#, Cheung K.L.^#, Liu, Henggui#, Tan, Z., Xian, Tang, Kang, Yuanxi, Du, Yanhua, Wang, Haibo, Liu, L., & Chen, Z. (2013). Potentiating functional antigen-specific CD8+ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Mol Ther. 2013 Jul; 21(7): 1445-1455. [1/10] [IF: 12.701] Medicine, (miscellaneous) 48/2447.
Zhou, J., Cheung, K.L., Tan, Z., Wang, H., Yu, W., Du, Y., Liu, L., Yuen, K., & Chen, Z. (2013). PD1-based vaccine amplifies CD8+ T cell immunity in mice. J Clin Invest. 2013 Jun; 123(6):2629-42. Medicine, (miscellaneous) 24/2447.

# First/Co-first author; corresponding/co-corresponding author

Grants

General Research Fund 2023/24, 24110323 ‘Deciphering T helper-2 cell immunity in cancer liver metastasis-associated immunotherapy resistance’. 01-Jan-2024 to 31-Dec-2026, HK$1,573,774.

General Research Fund 2022/23, Mechanistic delineation of hepatoma-intrinsic FADD in modulating anti-tumor CD8+T cell response. RGC, HK$883,197. 01-Jan-2023 to 31-Dec-2024

General Research Fund 2020/21, Delineating the immunoregulatory role of cholesterol on natural killer T cells in cancer liver metastases. RGC, HK$996,285. 01-Jan-2021 to 31-Dec-2023

Health and Medical Research Fund 2020, Improving liver cancer immunotherapy by co-targeting monocytic myeloid-derived suppressor cells. FHB, HK$1,000,000. 1-Sep-2020 to 31-Aug-2022

General Research Fund 2019/20, Mechanistic delineation of myeloid CCRK signaling in tumor immunosuppression’. RGC, HK$1,004,845. 1-Jan-2020 to 31-Dec-2021

AstraZeneca Oncology Pre-clinical Research Programme 2017, Enhancement of Hepatocellular Carcinoma Immunotherapy through mTOR Inhibition. AstraZeneca, HK$400,000. 30-Nov-2017 to 29-Nov-2019